<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869165</url>
  </required_header>
  <id_info>
    <org_study_id>16.0428</org_study_id>
    <nct_id>NCT02869165</nct_id>
  </id_info>
  <brief_title>Vaginal and Urinary Microbiome Trial</brief_title>
  <official_title>The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial looking at the effects of vaginal estrogen and a nonhormonal
      alternative on the vaginal and urinary microbiome in women with genitourinary syndrome of
      menopause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study is looking at the effects of vaginal estrogen and a nonhormonal alternative
      on the vaginal and urinary microbiome in women with genitourinary syndrome of menopause with
      the primary objective is to describe the bacterial communities associated in the vagina and
      urine of postmenopausal women receiving treatment for genitourinary syndrome of menopause
      with Premarin速 vaginal cream and a nonhormonal alternative, such as, apricot kernel oil. The
      participants will be randomized to either Premarin vaginal cream or apricot kernel oil. They
      will be given validated questionnaires to assess their urinary and vaginal symptoms, sexual
      function, quality of life, and impressions of severity and improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal and urinary predominance of anaerobic/fastidious taxonomy of micro-organisms on genomic, microbial DNA analysis of vaginal and urinary specimens.</measure>
    <time_frame>3 months</time_frame>
    <description>Predominance (greater than 50%) in vaginal and urinary specimen of anaerobic and/or fastidious organisms in the study population, to be compared between the control (Premarin速 vaginal estrogen) group and apricot kernel oil group. The primary analysis will compare the prevalence of genomic taxonomic anaerobic and/or fastidious organism predominance (&gt;50%) between the estrogen group and the non-estrogen alternative group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vaginal symptom questionnaire (VSQ)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in vaginal symptoms as assessed by vulvovaginal symptom questionnaire (VSQ) at baseline and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal and urinary predominance of anaerobic/fastidious taxonomy of micro-organisms on genomic, microbial DNA analysis of vaginal and urinary specimens.</measure>
    <time_frame>3 months</time_frame>
    <description>Predominance (greater than 50%) in vaginal and urinary specimen of anaerobic and/or fastidious organisms in the study population, to be compared between the control (Premarin速 vaginal estrogen) group and apricot kernel oil group. The primary analysis will compare the prevalence of genomic taxonomic anaerobic and/or fastidious organism predominance (&gt;50%) between the baseline patients and the patients at 3 months and compare the change in prevalence in this taxonomic predominance between the two study groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Atrophic Vaginitis</condition>
  <condition>Menopause</condition>
  <condition>Recurrent Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Premarin vaginal cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Premarin vaginal cream 1 gram will be inserted into the vaginal three times were week at nights for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apricot kernel oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One teaspoonful will be applied per vagina nights for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin vaginal cream</intervention_name>
    <description>Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.</description>
    <arm_group_label>Premarin vaginal cream</arm_group_label>
    <other_name>Conjugated equine estrogen topical cream</other_name>
    <other_name>Vaginal estrogen cream</other_name>
    <other_name>CEE topical cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apricot kernel oil</intervention_name>
    <description>Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.</description>
    <arm_group_label>Apricot kernel oil</arm_group_label>
    <other_name>Natural oil</other_name>
    <other_name>Organic oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-years old

          -  Women who qualify for vaginal estrogen

          -  Suitability for follow-up

        Exclusion Criteria:

          -  Age &lt; 18-years old

          -  Known allergic reaction or other adverse reactions to Premarin速 or any of its
             components or apricot kernel oil.

          -  Inability to apply the treatment as indicated because of other limitations.

          -  Already using another form of vaginal estrogen or apricot kernel oil other
             non-hormonal vaginal moisturizer in the past two weeks.

          -  Known active vaginal infection (symptomatic and/or untreated) or completion of
             treatment for bacterial vaginosis or cervical/vaginal infection within one week of
             recruitment.

          -  History of recurrent or chronic bacterial vaginosis with &gt; 2 episodes per year or
             symptoms reported for &gt; 6 months out of the last year.

          -  History of active vaginal ulcerative disease (active ulcers from atrophy, herpes
             symptoms at recruitment or herpes with &gt;2 outbreaks per year or last outbreak &lt;1month
             ago.

          -  Chronic antibiotic or probiotic use for indications not listed.

          -  Pelvic organ prolapse beyond the hymenal ring.

          -  Using a vaginal pessary , vaginal hormonal ring, or indwelling urinary catheter

          -  Evidence of active urinary tract infection by history and symptoms, urine dipstick or
             urine culture on day of presentation or within last 2 weeks.

          -  Recurrent or chronic bacterial vaginosis or recurrent or chronic urinary tract
             infection 3 episodes with the last year or 2 episodes within the last 6 months.

          -  History of deep venous thrombosis or pulmonary embolism or genetic predisposition to
             thromboembolism.

          -  History of an estrogen dependent cancer.

          -  Vaginal mesh erosion.

          -  Active vulvar dermatoses and on chronic topical steroids.

          -  Inability to speak or read English.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Meriwether, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherree Goss, RN</last_name>
    <phone>1-502-588-4333</phone>
    <email>skgoss01@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deslyn Hobson, M.D.</last_name>
    <phone>1-502-561-7260</phone>
    <email>deslyn.hobson@louisville.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Care Outpatient Center and University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherree Goss, RN</last_name>
      <phone>502-588-4333</phone>
      <email>skgoss01@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Kate Meriwether, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Francis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deslyn Hobson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Casey Kinman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf</url>
    <description>Age and sex composition: 2010 Census Briefs</description>
  </link>
  <results_reference>
    <citation>Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2.</citation>
    <PMID>23985562</PMID>
  </results_reference>
  <results_reference>
    <citation>Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, Kingsberg SA. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013 Jul 29;5:437-47. doi: 10.2147/IJWH.S44579. Print 2013.</citation>
    <PMID>23935388</PMID>
  </results_reference>
  <results_reference>
    <citation>Danforth KN, Townsend MK, Lifford K, Curhan GC, Resnick NM, Grodstein F. Risk factors for urinary incontinence among middle-aged women. Am J Obstet Gynecol. 2006 Feb;194(2):339-45.</citation>
    <PMID>16458626</PMID>
  </results_reference>
  <results_reference>
    <citation>Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994 Jan;61(1):178-80.</citation>
    <PMID>8293835</PMID>
  </results_reference>
  <results_reference>
    <citation>Siddiqui H, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol. 2011 Nov 2;11:244. doi: 10.1186/1471-2180-11-244.</citation>
    <PMID>22047020</PMID>
  </results_reference>
  <results_reference>
    <citation>Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001500. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD001500.</citation>
    <PMID>17054136</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, Romero R. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011 Apr;118(5):533-49. doi: 10.1111/j.1471-0528.2010.02840.x. Epub 2011 Jan 20. Review.</citation>
    <PMID>21251190</PMID>
  </results_reference>
  <results_reference>
    <citation>Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa R, Koenig D, Gloor GB, Reid G. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One. 2011;6(11):e26602. doi: 10.1371/journal.pone.0026602. Epub 2011 Nov 2.</citation>
    <PMID>22073175</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin DH. The microbiota of the vagina and its influence on women's health and disease. Am J Med Sci. 2012 Jan;343(1):2-9. doi: 10.1097/MAJ.0b013e31823ea228. Review.</citation>
    <PMID>22143133</PMID>
  </results_reference>
  <results_reference>
    <citation>Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996 Apr;23(3):259-63.</citation>
    <PMID>8794418</PMID>
  </results_reference>
  <results_reference>
    <citation>Coyne KS, Margolis MK, Thompson C, Kopp Z. Psychometric equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish. Value Health. 2008 Dec;11(7):1096-101. doi: 10.1111/j.1524-4733.2008.00346.x. Epub 2008 May 16.</citation>
    <PMID>18489500</PMID>
  </results_reference>
  <results_reference>
    <citation>Rogers RG, Rockwood TH, Constantine ML, Thakar R, Kammerer-Doak DN, Pauls RN, Parekh M, Ridgeway B, Jha S, Pitkin J, Reid F, Sutherland SE, Lukacz ES, Domoney C, Sand P, Davila GW, Espuna Pons ME. A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). Int Urogynecol J. 2013 Jul;24(7):1091-103. doi: 10.1007/s00192-012-2020-8. Epub 2013 Apr 30.</citation>
    <PMID>23632798</PMID>
  </results_reference>
  <results_reference>
    <citation>Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer. 2001 Jan;37(2):189-97.</citation>
    <PMID>11166145</PMID>
  </results_reference>
  <results_reference>
    <citation>Jelovsek JE, Barber MD. Women seeking treatment for advanced pelvic organ prolapse have decreased body image and quality of life. Am J Obstet Gynecol. 2006 May;194(5):1455-61.</citation>
    <PMID>16647928</PMID>
  </results_reference>
  <results_reference>
    <citation>Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33.</citation>
    <PMID>8628042</PMID>
  </results_reference>
  <results_reference>
    <citation>Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003 Jul;189(1):98-101.</citation>
    <PMID>12861145</PMID>
  </results_reference>
  <results_reference>
    <citation>Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009 Jul-Aug;16(4):735-41. doi: 10.1097/gme.0b013e318199e734.</citation>
    <PMID>19252451</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008 Jul-Aug;15(4 Pt 1):661-6. doi: 10.1097/gme.0b013e31815a5168.</citation>
    <PMID>18698279</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014 Dec;124(6):1147-56. doi: 10.1097/AOG.0000000000000526. Review.</citation>
    <PMID>25415166</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahn DD, Ward RM, Sanses TV, Carberry C, Mamik MM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J. 2015 Jan;26(1):3-13. doi: 10.1007/s00192-014-2554-z. Epub 2014 Nov 13. Review.</citation>
    <PMID>25392183</PMID>
  </results_reference>
  <results_reference>
    <citation>Erekson EA, Yip SO, Wedderburn TS, Martin DK, Li FY, Choi JN, Kenton KS, Fried TR. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013 Sep;20(9):973-9. doi: 10.1097/GME.0b013e318282600b.</citation>
    <PMID>23481118</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Kate V. Meriwether</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Atrophic Vaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

